8-K: InspireMD Reports Strong Q4 2025 Revenue Growth, Eyes TCAR Market

InspireMD, Inc. announced robust fourth-quarter and full-year 2025 financial results, driven by CGuard Prime's U.S. launch and international demand, alongside strategic advancements in TCAR procedures.

Summary

• Total revenue for the fourth quarter of 2025 was $3.1 million, a 62% increase year-over-year, and $9.0 million for the full year 2025, up 28% from 2024.
• U.S. revenue for Q4 2025 reached $0.9 million, showing 74% sequential growth during the second quarter of CGuard Prime's launch.
• International revenue for Q4 2025 was $2.3 million, a 17% increase over Q4 2024, and $7.6 million for the full year 2025, an 8% increase over 2024.
• Gross profit for Q4 2025 was $1.2 million (37.5% margin), up from $0.5 million (24.1% margin) in Q4 2024, driven by a favorable shift to higher-margin U.S. sales.
• Net loss for Q4 2025 was $11.8 million, or $0.14 per basic and diluted share, compared to a net loss of $9.2 million, or $0.19 per basic and diluted share, for Q4 2024.
• Full year 2025 net loss was $48.8 million, or $0.76 per basic and diluted share, compared to $32.0 million, or $0.76 per basic and diluted share, for full year 2024.
• Cash and cash equivalents and marketable securities stood at $54.2 million as of December 31, 2025, an increase from $34.6 million as of December 31, 2024.
• The company completed enrollment in the CGUARDIANS II pivotal trial for CGuard Prime in transcarotid artery revascularization (TCAR) procedures and submitted a PMA-S to the FDA for this indication.
• Management expects full year 2026 revenue to be in the range of $13 million to $15 million, representing approximately 45% to 65% growth over 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting strong commercial momentum and strategic advancements, though tempered by increased operating expenses and continued net losses typical of a growth-stage medical device company.

Positives

• Total revenue increased by 62% year-over-year to $3.1 million in Q4 2025 and by 28% to $9.0 million for the full year 2025.
• U.S. revenue for CGuard Prime showed strong sequential growth of 74% in Q4 2025, indicating robust early commercial traction.
• Gross profit margin significantly improved to 37.5% in Q4 2025 from 24.1% in Q4 2024, driven by a favorable shift towards higher-margin U.S. sales.
• Completed enrollment in the CGUARDIANS II pivotal trial and submitted a PMA-S to the FDA for CGuard Prime in TCAR procedures, potentially doubling the addressable U.S. market.
• Cash and cash equivalents and marketable securities increased to $54.2 million as of December 31, 2025, from $34.6 million at December 31, 2024, providing enhanced liquidity.
• Management provided a positive 2026 revenue outlook, projecting $13 million to $15 million, reflecting 45% to 65% growth over 2025.

Negatives

• Net loss for Q4 2025 increased to $11.8 million from $9.2 million in Q4 2024.
• Full year 2025 net loss increased significantly to $48.8 million from $32.0 million in full year 2024.
• Total operating expenses for Q4 2025 increased by $3.5 million to $13.3 million, and for the full year 2025 by $17.3 million to $52.3 million, primarily due to U.S. commercial launch investments.
• Financial income, net for the full year 2025 decreased by $0.7 million to $0.9 million compared to full year 2024.
• Significant shareholder dilution occurred, with weighted average common stock increasing from 41.9 million shares in 2024 to 64.3 million shares in 2025, contributing to the same net loss per share despite a larger net loss.

Risks

• History of recurring losses and negative cash flows from operating activities, significant future commitments, and uncertainty regarding the adequacy of liquidity to pursue complete business objectives, raising substantial doubt about the ability to continue as a going concern.
• Need to raise additional capital to meet business requirements in the future, which may be costly or difficult to obtain and could dilute stockholders' ownership interests.
• Risks associated with the clinical development, commercialization, and market acceptance of products.
• Uncertainty regarding whether clinical trial results for products will be predictive of real-world results.
• Inability to secure and maintain regulatory approvals for the sale of products.
• Negative clinical trial results or lengthy product delays in key markets.
• Ability to maintain compliance with Nasdaq listing standards.
• Ability to generate significant revenues from products.
• Estimates of expenses, future revenues, capital requirements, and the ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of products.
• Dependence on a single manufacturing facility and the ability to comply with stringent manufacturing quality standards and to increase production as necessary.
• Risk that data collected from current and planned clinical trials may not be sufficient to demonstrate that technology is an attractive alternative to other procedures and products.
• Intense competition in the industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution, and personnel resources.
• Entry of new competitors and products and potential technological obsolescence of products.
• Inability to carry out research, development, and commercialization plans.
• Loss of a key customer or supplier.
• Technical problems with research and products and potential product liability claims; product malfunctions; price increases for supplies and components.
• Whether access to products is achieved in a commercially viable manner and whether products receive adequate reimbursement by governmental and other third-party payers.
• Efforts to successfully obtain and maintain intellectual property protection covering products may not be successful.
• Adverse federal, state, and local government regulation in the United States, Europe, Israel, and other foreign jurisdictions.
• Conducting business in multiple foreign jurisdictions, exposing the company to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws, and political and economic instability in each jurisdiction.
• Security, political, and economic instability in the Middle East that could harm the business, including due to the current security situation in Israel.
• Current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.
• Changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements and the impact of such policies on the company, its customers and suppliers, and the global economic environment.

Future Outlook

Management expects revenue for the full year 2026 to be in the range of $13 million to $15 million, reflecting expected revenue growth of approximately 45% to 65% over 2025. The company anticipates more catalysts in 2026 that may accelerate the adoption of its next-generation stent platform and business growth. Approval for CGuard Prime in TCAR procedures is expected to potentially double the addressable U.S. market opportunity.

Management Comments

• "We continue to see robust early momentum in our U.S. business with CGuard Prime and growing demand internationally for CGuard as we build a platform designed to position us to be a global leader in the treatment of carotid artery disease and the prevention of stroke."
• "In addition, we are committed to advancing CGuard Prime for use in TCAR procedures. Once approved, this will potentially double our addressable U.S. market opportunity."
• "We expect more catalysts in 2026 that may accelerate the adoption of our next-generation stent platform and the growth of our business."

Industry Context

StockSavvy.ai notes that InspireMD's focus on carotid artery disease and stroke prevention with its CGuard Prime system positions it in a competitive medical device market. The pursuit of TCAR indications aligns with a trend towards less invasive procedures, potentially expanding its market share against traditional surgical methods and other stent manufacturers. The strong international growth also suggests effective market penetration beyond the U.S.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Stakeholder Impact

• Shareholders: Potential for future growth driven by CGuard Prime's market penetration and TCAR expansion, but also face ongoing dilution risk from capital raises and continued net losses.
• Employees: Increased headcount-related expenses for the U.S. commercial team indicate growth in employment opportunities.
• Customers (hospitals and integrated delivery networks): Continued adoption of CGuard Prime, with over 500 cumulative procedures, suggests positive reception and potential for broader use.
• Creditors: The increased cash and marketable securities position provides improved liquidity, potentially reducing short-term credit risk.

Next Steps

• Anticipate more catalysts in 2026 to accelerate the adoption of the next-generation stent platform and business growth.
• Await FDA approval for CGuard Prime for use in TCAR procedures, which could potentially double the addressable U.S. market opportunity.
• Management will host a conference call on March 18, 2026, to review financial results and provide corporate updates.

Key Dates

Recommendation

While InspireMD demonstrates strong revenue growth and strategic progress with CGuard Prime and TCAR indications, the company continues to incur significant net losses and operating expenses as it scales. The substantial increase in cash from a likely capital raise provides liquidity but also indicates ongoing cash burn and shareholder dilution. The positive outlook for 2026 revenue is encouraging, but the company's history of recurring losses and the need for future capital raises, as highlighted in the risks, suggest a 'hold' position until there is clearer visibility on profitability or sustained positive cash flow.

Keywords

InspireMD, NSPR, CGuard Prime, carotid stent, stroke prevention, TCAR, FDA, medical device, financial results, Q4 2025, full year 2025, CGUARDIANS II trial